MNKD Mannkind Corp

Price (delayed)

$4.36

Market cap

$1.09B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.27

Enterprise value

$1.17B

MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, its ...

Highlights
Mannkind's gross profit has increased by 31% YoY and by 2.8% from the previous quarter
Mannkind's gross margin has increased by 22% YoY
The company's debt has surged by 174% YoY and by 169% QoQ
Mannkind's net income has decreased by 31% YoY and by 6% from the previous quarter

Key stats

What are the main financial stats of MNKD
Market
Shares outstanding
249.16M
Market cap
$1.09B
Enterprise value
$1.17B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
16.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
17.63
Earnings
Revenue
$66.35M
EBIT
-$47.46M
EBITDA
-$43.99M
Free cash flow
-$31.27M
Per share
EPS
-$0.27
Free cash flow per share
-$0.13
Book value per share
-$0.7
Revenue per share
$0.27
TBVPS
$1.29
Balance sheet
Total assets
$319.38M
Total liabilities
$493M
Debt
$331.46M
Equity
-$173.62M
Working capital
$215.23M
Liquidity
Debt to equity
-1.91
Current ratio
3.94
Quick ratio
3.84
Net debt/EBITDA
-1.9
Margins
EBITDA margin
-66.3%
Gross margin
62.7%
Net margin
-91.7%
Operating margin
-61.8%
Efficiency
Return on assets
-38.8%
Return on equity
N/A
Return on invested capital
-33%
Return on capital employed
-19.3%
Return on sales
-71.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MNKD stock price

How has the Mannkind stock price performed over time
Intraday
6.34%
1 week
6.86%
1 month
1.16%
1 year
159.52%
YTD
39.3%
QTD
11.22%

Financial performance

How have Mannkind's revenue and profit performed over time
Revenue
$66.35M
Gross profit
$41.62M
Operating income
-$41.02M
Net income
-$60.83M
Gross margin
62.7%
Net margin
-91.7%
Mannkind's net income has decreased by 31% YoY and by 6% from the previous quarter
Mannkind's gross profit has increased by 31% YoY and by 2.8% from the previous quarter
The company's net margin fell by 22% YoY and by 4.3% QoQ
Mannkind's gross margin has increased by 22% YoY

Growth

What is Mannkind's growth rate over time

Valuation

What is Mannkind stock price valuation
P/E
N/A
P/B
N/A
P/S
16.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
17.63
Mannkind's EPS has decreased by 17% YoY and by 3.8% from the previous quarter
The equity has increased by 12% year-on-year and by 3.8% since the previous quarter
The P/S is 77% higher than the 5-year quarterly average of 8.6 and 60% higher than the last 4 quarters average of 9.5
The revenue has grown by 7% YoY

Efficiency

How efficient is Mannkind business performance
The company's return on invested capital rose by 41% QoQ
The ROA is up by 34% QoQ and by 27% YoY
Mannkind's ROS has decreased by 27% YoY but it has increased by 3% from the previous quarter

Dividends

What is MNKD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MNKD.

Financial health

How did Mannkind financials performed over time
The company's total assets is 35% lower than its total liabilities
The company's total assets has surged by 194% QoQ
MNKD's total liabilities has surged by 77% year-on-year and by 71% since the previous quarter
The debt to equity has dropped by 181% since the previous quarter
The company's debt has surged by 174% YoY and by 169% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.